Free Trial

Centene (CNC) Expected to Announce Earnings on Wednesday

Centene logo with Medical background

Key Points

  • Centene is expected to announce its Q3 2025 earnings on October 29, with analysts forecasting a loss of ($0.18) per share and revenues of $47.5 billion.
  • After missing earnings expectations in the previous quarter, Centene reported revenues of $48.74 billion, significantly exceeding consensus estimates.
  • Analysts have revised Centene's price targets downward, with ratings ranging from "Buy" to "Sell," reflecting mixed sentiments about the stock's future performance.
  • Interested in Centene? Here are five stocks we like better.

Centene (NYSE:CNC - Get Free Report) is expected to be posting its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect Centene to post earnings of ($0.18) per share and revenue of $47.5021 billion for the quarter. Centene has set its FY 2025 guidance at 1.750-1.750 EPS.Parties may review the information on the company's upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, October 29, 2025 at 9:00 AM ET.

Centene (NYSE:CNC - Get Free Report) last issued its quarterly earnings data on Friday, July 25th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.39). The business had revenue of $48.74 billion for the quarter, compared to the consensus estimate of $44.71 billion. Centene had a net margin of 1.15% and a return on equity of 9.57%. Centene's revenue was up 22.4% compared to the same quarter last year. During the same period in the previous year, the business posted $2.42 EPS. On average, analysts expect Centene to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Centene Stock Performance

CNC stock opened at $36.10 on Wednesday. The firm has a 50 day moving average of $32.57 and a two-hundred day moving average of $43.27. Centene has a 12 month low of $25.08 and a 12 month high of $70.11. The company has a market capitalization of $17.73 billion, a price-to-earnings ratio of 8.94, a P/E/G ratio of 1.40 and a beta of 0.48. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.64.

Insider Activity

In other news, Director Theodore R. Samuels II acquired 9,000 shares of Centene stock in a transaction on Monday, July 28th. The stock was bought at an average price of $27.62 per share, for a total transaction of $248,580.00. Following the transaction, the director owned 32,000 shares of the company's stock, valued at $883,840. The trade was a 39.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Sarah London acquired 19,230 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were purchased at an average cost of $25.50 per share, for a total transaction of $490,365.00. Following the acquisition, the chief executive officer directly owned 845,275 shares in the company, valued at $21,554,512.50. This represents a 2.33% increase in their position. The disclosure for this purchase can be found here. Insiders own 0.36% of the company's stock.

Institutional Investors Weigh In On Centene

Institutional investors and hedge funds have recently bought and sold shares of the business. B. Riley Wealth Advisors Inc. acquired a new position in shares of Centene in the 2nd quarter valued at $281,000. Advisory Services Network LLC increased its stake in Centene by 352.6% in the second quarter. Advisory Services Network LLC now owns 16,747 shares of the company's stock valued at $909,000 after acquiring an additional 13,047 shares during the period. Geneos Wealth Management Inc. raised its position in Centene by 29.8% in the second quarter. Geneos Wealth Management Inc. now owns 1,897 shares of the company's stock worth $103,000 after purchasing an additional 435 shares in the last quarter. Caxton Associates LLP boosted its holdings in Centene by 21.4% during the second quarter. Caxton Associates LLP now owns 7,291 shares of the company's stock valued at $396,000 after purchasing an additional 1,283 shares in the last quarter. Finally, Headlands Technologies LLC grew its stake in shares of Centene by 1,236.2% in the 2nd quarter. Headlands Technologies LLC now owns 3,247 shares of the company's stock valued at $176,000 after purchasing an additional 3,004 shares during the period. Institutional investors own 93.63% of the company's stock.

Analysts Set New Price Targets

CNC has been the topic of several analyst reports. JPMorgan Chase & Co. lowered their target price on shares of Centene from $48.00 to $30.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 29th. Mizuho upped their price target on Centene from $28.00 to $40.00 and gave the stock a "neutral" rating in a research note on Thursday, October 9th. Bank of America downgraded Centene from a "neutral" rating to an "underperform" rating and cut their price objective for the company from $52.00 to $30.00 in a research note on Wednesday, July 16th. Robert W. Baird decreased their target price on Centene from $68.00 to $28.00 and set a "neutral" rating for the company in a research report on Friday, July 25th. Finally, Barclays lifted their price target on shares of Centene from $33.00 to $35.00 and gave the company an "equal weight" rating in a research report on Friday, September 12th. Three research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $39.50.

Read Our Latest Research Report on Centene

Centene Company Profile

(Get Free Report)

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support.

Further Reading

Earnings History for Centene (NYSE:CNC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Centene Right Now?

Before you consider Centene, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centene wasn't on the list.

While Centene currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.